An Insight from the Tebubio Team
Discover how CleanCap® technology is revolutionising mRNA-based therapeutics by enhancing mRNA stability and translation.
Get the opportunity to access all the best tools, in one place, for advancing your mRNA therapeutic research thanks to Tebubio.
mRNA-Based Therapeutics: Pioneering the Future of Medicine
Over the past few years, mRNA-based therapeutics have emerged as a promising approach to treat various diseases, including cancer, infectious diseases, and genetic disorders. This revolutionary technology works by delivering synthetic mRNA into cells, empowering them to produce therapeutic proteins or antigens tailored to fight specific conditions.
To achieve this, a critical step involves In Vitro Transcription (IVT). IVT synthesizes mRNA using purified RNA polymerase, a DNA template with the target gene, and modified NTPs as building blocks. This precise process produces high-fidelity mRNA tailored for therapeutic proteins, antigens, or gene-editing, highlighting IVT’s crucial role in next-generation therapeutics.
Capping in IVT mRNA: Enhancing Stability and Efficacy in Therapeutic Applications
Given its transformative potential in vaccines and gene therapy, IVT of mRNA has gained significant attention in recent years as a key technology driving therapeutic innovations.
This advanced technique enables the production of mRNA molecules outside living cells, enabling precise control over their composition and structure, which is critical for clinical applications.
Plus, a key feature of IVT mRNA is the addition (capping) of a protective cap structure at the 5’ end (5’ cap), which enhances stability and translation by mimicking natural cellular modifications, protecting mRNA from rapid degradation, and improving recognition by the cell’s translation machinery—critical for effective therapeutic use.
CleanCap® Technology: Setting New Standards in mRNA Manufacturing
As previously mentioned, capping significantly enhances the efficiency of in vitro transcription—essential for therapeutic applications.
TriLink, a pioneer in mRNA research and a long-standing partner, has led innovation in this field. In 2016, they revolutionised capped mRNA production with the introduction of CleanCap® nucleotides.
CleanCap® technology enables co-transcriptional capping with a CAP1 structure during IVT, simplifying the process while ensuring exceptional consistency with nearly 100% capped molecules and minimal batch-to-batch variation. The robustness and efficiency of CleanCap® have set a new standard in mRNA manufacturing, enhancing the stability and translation efficiency of mRNA therapeutics and vaccines.
IVT Mix Protocol - Transcription Reaction Tabler
A reaction of 1 ml would provide 5 mg of capped mRNA.
It also means that the smallest reaction with 20 µL would provide 100 µg.
This yield is possible for mRNA around 1-3 kb long and only if you use the validated enzymes and buffer.
Tebubio: Faciliting Your Research with One-Stop Access
Are you interested in optimising your mRNA stability and translation efficiency with CleanCap® Technology?
We offer, all in one place, a comprehensive range of reagents optimised and validated for CleanCap® M6, namely:
- CleanCap® Reagent M6 for the best capping
- NTPs including modified nucleotides such as N1-methyl-PseudoU
- T7 RNA polymerase
- CleanScribe™ RNA Polymerase, novel enzyme that reduces double-stranded RNA (dsRNA) levels by up to 85% in IVT
- Inorganic pyrophosphatase
Diana Perrier, Marketing Manager
Marketing Team at Tebubio
"The minRNA allows therapeutics development without the need to design UTRs anymore. It means saving many months of research. MinRNA would become the highway to success."
Name goes here
Position goes here
Description goes here
-
References
1. Mamaghani S, Penna RR, Frei J, Wyss C, Mellett M, Look T, Weiss T, Guenova E, Kündig TM, Lauchli S, et al. Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo. Cells. 2024; 13(15):1242. https://doi.org/10.3390/cells13151242
Explore RNA Based Therapeutic Discovery Services
Our Contract Reserach Services experts support mRNA synthesis, optimization, and RNA-based therapeutic discovery. Learn how we can partner to advance your research.